Abstract
AbstractCell therapy research in Parkinson's disease (PD) seeks to develop this approach into a clinically competitive treatment. It should be emphasized, though, that during the more than 20 years since the clinical cell therapy trials started, several new therapeutic options for the PD patient have been added. Most importantly, deep-brain stimulation (DBS), in most cases in the subthalamic nucleus, has been developed and shown to substantially improve motor deficits in advanced PD. Therefore, in order to become clinically useful, cell replacement has to give rise to long-lasting, major improvement in mobility, suppression of dyskinesias, and amelioration of symptoms resistant to other treatments or to counteract disease progression. This chapter describes what has been learned from the clinical trials with transplantation of human embryonic mesencephalic tissue in patients with PD, the major scientific and clinical problems to be solved, and how far stem cells have reached toward the clinical application.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
